Delving into the Latest Updates on SKB-500 with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

SKB500

Target

CD276

Mechanism

CD276 modulators(CD276 antigen modulators)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Sichuan Kelun Botai Biomedicine Co., Ltd.

Active Organization

Sichuan Kelun Botai Biomedicine Co., Ltd.

Sichuan Kelun Pharmacy Institute Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估SKB500在晚期实体瘤受试者中的安全性和耐受性、剂量限制性毒性（DLT），确定最大耐受剂量（MTD）或最大给药剂量（MAD），以及Ⅱ期推荐剂量（RP2D）。次要目的： 1) 评估SKB500在晚期实体瘤受试者中的药代动力学（PK）特征； 2) 评估SKB500在晚期实体瘤受试者中的免疫原性； 3) 初步评估SKB500在晚期实体瘤受试者中的抗肿瘤活性。

[Translation]

Primary objectives: Evaluate the safety and tolerability of SKB500 in subjects with advanced solid tumors, dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the recommended dose for Phase II (RP2D). Secondary objectives: 1) Evaluate the pharmacokinetic (PK) characteristics of SKB500 in subjects with advanced solid tumors; 2) Evaluate the immunogenicity of SKB500 in subjects with advanced solid tumors; 3) Preliminary evaluation of the anti-tumor activity of SKB500 in subjects with advanced solid tumors.

Start Date09 Dec 2024

Sponsor / Collaborator

Sichuan Kelun Botai Biomedicine Co., Ltd.

100 Clinical Results associated with SKB-500

Login to view more data

100 Translational Medicine associated with SKB-500

Login to view more data

100 Patents (Medical) associated with SKB-500

Login to view more data

100 Deals associated with SKB-500

Login to view more data